Clinical case of acquired hemophilia combined with antiphospholipid syndrome: 616.151.514:616-005.1

Abstract

Summary. Acquired coagulopathy, caused by the formation of inhibitory autoantibodies to endogenous factors of the blood coagulation system, belongs to the group of rare and life-threatening diseases. The most prevalent among these conditions is acquired hemophilia, which is characterized by the formation of a specific inhibitor to plasma coagulation factor VIII and is clinically manifested by extensive spontaneous hematomas and other massive bleeding of various localization. This article presents a rare clinical case of a combination of acquired hemophilia and antiphospholipid syndrome (APS) in a patient with a history of autoimmune rheumatological disease. APS and acquired hemophilia are two clinically and pathogenetically divergent conditions that are often associated with an autoimmune process and can be observed in the same patient.

For citation: Surenkov A. A., Orel E. B., Dvirnyk V. N., Yakovleva E. V., Dimitrieva O. S., Klychnikova E. V., Polyanskaya T.Yu., Zozulya N. I. Clinical case of acquired hemophilia combined with antiphospholipid syndrome. Tromboz, gemostaz i reologiya. 2024;(4):81–86. (In Russ.).

References

1. Franchini M., Vaglio S., Marano G. et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017;22(9):514–20. DOI: 10.1080/10245332.2017.1319115.
2. Al Mahmasani L., Finianos A., Bou-F akhredin R. et al. Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding. Expert Opinion Orphan Drugs. 2020;8(2–3):79– 89. DOI: 10.1080/21678707.2020.1740682.
3. Mingot-Castellano M. E., Núñez R., Rodríguez-M artorell F. J. Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc). 2017;148(7):314–22. DOI: 10.1016/j.medcle.2016.11.041.
4. Knoebl P., Marco P., Baudo F. et al.; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–31. DOI: 10.1111/j.1538-7836.2012.04654.x.
5. El Demerdash D. M., Ayad A., Tawfik N. Acquired hemophiliaA (AHA): underreported, underdiagnosed, undertreated medical condition. Egypt J Intern Med. 2022;34(1):12. DOI: 10.1186/ s43162-021-00074-9.
6. Pishko A. M., Doshi B. S. Acquired hemophilia A: current guidance and experience from clinical practice. J Blood Med. 2022;13:255– 65. DOI: 10.2147/JBM.S284804.
7. Nowak K. M., Carpinteiro A., Szalai C., Saner F. H. Acquired hemophilia A: A permanent challenge for all physicians. Medicines (Basel). 2022;9(3):21. DOI: 10.3390/medicines9030021.
8. Regino C. A., Alvarez J. C., Mejía Buriticá L. et al. Idiopathic acquired hemophilia A, a rare cause of bleeding: A case report and literature review. Am J Case Rep. 2021;22: e929401. DOI: 10.12659/ AJCR.929401.
9. Pai M. Acquired hemophilia A. Hematol Oncol Clin North Am. 2021;35(6):1131–42. DOI: 10.1016/j.hoc.2021.07.007.
10. Surenkov A. A., Orel E. B., Zozulya N. I., Dvirnyk V. N. Features of clinical and laboratory diagnosis of rare coagulopathy — a cquired hemophilia. Gematologiya i transfuziologiya. 2022;67(4):535–50. (In Russ.). DOI: 10.35754/0234-5730-2022-67-4-535-550.
11. Casas Patarroyo C. P., Agudelo Lopez C. D.P., Galvez K. et al. Importancia de la orientacióndiagnóstica en hemofilia A adquirida. Rev Med Chil. 2019;147(3):334–41. (In Spanish). DOI: 10.4067/ S0034-98872019000300334.
12. Tiede A., Collins P., Knoebl P. et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791–801. DOI: 10.3324/haematol.2019.230771.
13. Galstyan G. M., Nalbandyan S. A., Sabirov K. R. et al. Treatment tactics for a patient with acquired hemophilia: continuous infusion of recombinant activated coagulation factor VII and the inhibitor eradication. Gematologiya i transfuziologiya. 2022;67(2):282–94. (In Russ.). DOI: 10.35754/0234-5730-2022-67-2-282-294.
14. Coppola A., Franchini M., Tripodi A. et al.; ad hoc Working Group (Appendix 1). Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. Blood Transfus. 2022; 20(3):245–62. DOI: 10.2450/2022.0238-21.
15. Tiede A., Klamroth R., Scharf R. E. et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125(7):1091–7. DOI: 10.1182/ blood-2014-07-587089.
16. Collins P., Baudo F., Knoebl P. et al.; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012;120(1):47–55. DOI: 10.1182/blood-2012-02-409185.
17. Ames P. R., Graf M., Archer J. et al. Prolonged activated partial thromboplastin time: Difficulties in discriminating coexistent factor VIII inhibitor and lupus anticoagulant. Clin Appl Thromb Hemost. 2015;21(2):149–54. DOI: 10.1177/1076029614541516.
18. Chen V., Roby L. C., Wentzel S. et al. Acquired hemophilia A inthe setting of dual anticoagulation therapy and lupus anticoagulant: a case report. J Med Case Rep. 2022;16(1):177. DOI: 10.1186/ s13256-022-03402-x.
19. Tiede A., Werwitzke S., Scharf R. E. Laboratory diagnosis of acquired hemophilia A: Limitations, consequences and challenges. Semin Thromb Hemost.2014;40(7):803–11. DOI: 10.1055/s-0034-1390004.
20. Gupta D., Chatterjee T., Sharma A. et al. Rare case of acquired haemophilia and lupus anticoagulant. Indian J Hematol Blood Transfus. 2014;30(3):197–200. DOI: 10.1007/s12288-012-0204-5.